Stock Events

Stock Events

Calidi Biotherapeutics 

$0.57
0
-$0.18-23.77% Today

Statistics

Day High
0.59
Day Low
0.51
52W High
-
52W Low
-
Volume
914,218
Avg. Volume
-
Mkt Cap
4.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MarExpected
Q3 2025
Next
-2.21
-1.99
-1.78
-1.56
Expected EPS
-1.56
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-47.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLDI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics focuses on developing stem cell therapies for neurodegenerative diseases, similar to Calidi's focus on regenerative medicine.
Stem
STEM
Mkt Cap164.53M
Lineage Cell Therapeutics works on cell-based therapies, directly competing in the regenerative medicine space.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited specializes in regenerative medicine using mesenchymal lineage cells, aligning closely with Calidi's therapeutic approaches.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics develops programmed cellular immunotherapies, which competes with Calidi's approach in using biotherapeutics for treatment.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that can be seen as a competitor to traditional stem cell therapies.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation produces autologous cell therapies for treatment of severe diseases, directly competing with Calidi's cell therapy approaches.

About

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
Show more...
CEO
ISIN
US3207034089

Listings

OTC Link
US
CLDWW
ARCX
US
FLAG
XASE
US
CLDI
BOATS
BOATS
CLDI.BOATS

0 Comments

Share your thoughts

FAQ

What is Calidi Biotherapeutics stock price today?▼
The current price of CLDI.BOATS is $0.57 USD — it has decreased by -23.77% in the past 24 hours. Watch Calidi Biotherapeutics stock price performance more closely on the chart.
What is Calidi Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Calidi Biotherapeutics stocks are traded under the ticker CLDI.BOATS.
What is Calidi Biotherapeutics market cap?▼
Today Calidi Biotherapeutics has the market capitalization of 4.06M
When is the next Calidi Biotherapeutics earnings date?▼
Calidi Biotherapeutics is going to release the next earnings report on March 13, 2026.
What were Calidi Biotherapeutics earnings last quarter?▼
CLDI.BOATS earnings for the last quarter are -2.21 USD per share, whereas the estimation was -1.68 USD resulting in a -31.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Calidi Biotherapeutics revenue for the last year?▼
Calidi Biotherapeutics revenue for the last year amounts to 0 USD.
What is Calidi Biotherapeutics net income for the last year?▼
CLDI.BOATS net income for the last year is -47.63M USD.
When did Calidi Biotherapeutics complete a stock split?▼
Calidi Biotherapeutics has not had any recent stock splits.